Johnson & Johnson news

   Watch this stock
Showing stories 1 - 10 of about 132   

Articles published

JNJ 99.96 -0.26 (-0.26%)
price chart
Consumer group alleges 'reckless conduct' on part of Johnson & Johnson
A consumer advocacy group today requested that the U.S. Senate investigate Johnson & Johnson for what it called �a pattern of reckless conduct,� one month after calling on the Department of Justice to review whether the health care giant knowingly ...
The Bear Case Against Johnson & Johnson: Does It Hold Water?
During an eight-year run from 1994 to 2002, shares of health-care conglomerate Johnson & Johnson (NYSE: JNJ ) surged 500%.
Johnson & Johnson execs tout advances, hear criticism from patients at ...  The Star-Ledger
Johnson & Johnson Boosts Dividend By 6.1%  Wall Street Journal
Related articles »  
Johnson & Johnson Profit Jumps As Prescription Drug Sales Surge And Outlook ...
Johnson & Johnson, the maker of medicines like Tylenol and consumer products like Aveeno and Listerine, reported $18.1 billion in first quarter revenue, beating Street estimates of $17.99 billion and coming in 3.5% above the $17.5 billion reported for ...
Johnson & Johnson Earnings: Will Tuesday Bring More Good News for J&J?  Motley Fool
Johnson & Johnson Reports 2014 First-Quarter Results:  Wall Street Journal
Related articles »  
How Johnson & Johnson Became A Household Name
New Brunswick, N.J.-based Johnson & Johnson (NYSE:JNJ) is probably most famous as the parent company of multiple household products that double as household names.
Johnson & Johnson's New Diabetes Drug: A Blockbuster in the Making?
A major reason for that jump is a new wave of therapies, including Invokana, that are designed to improve how the body eliminates glucose.
Related articles »  
Why Johnson & Johnson Is Outperforming the Dow
Another health care stock, Johnson & Johnson (NYSE: JNJ ) , has gained nearly 9% to become the Dow's third best-performing stock this year.
Johnson & Johnson Announces Dividend Increase of 6.1%
NEW BRUNSWICK, N.J., April 24, 2014 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a 6.1% increase in the quarterly dividend rate, from $0.66 per share to $0.70 per share.
Johnson & Johnson Ending Plans for Botox Rival
But the product's development was marked by fits and starts. In recent years, J&J has kept pushing back the timeline for seeking regulatory approval.
J&J says halting development of Botox rival  Reuters
Related articles »  
Johnson & Johnson (JNJ) Raises Quarterly Dividend 6.1% to $0.70; 2.8% Yield
"In recognition of our 2013 results, strong financial position and confidence in the future of Johnson & Johnson, the Board has voted to increase the dividend for the 52nd consecutive year," said Alex Gorsky, Chairman and Chief Executive Officer of the ...
Johnson & Johnson's Kim Kadlec Departs For AOL
Kim Kadlec, worldwide VP of the global marketing group at Johnson & Johnson Johnson & Johnson for the past eight years, is moving to AOL AOL to be head of relationship management, a new position.
Johnson & Johnson's Kim Kadlec Joining AOL  Adweek
AOL's Latest Executive Hiring: Johnson & Johnson's Kadlec  Wall Street Journal (blog)
Related articles »